Tumor News and Research

RSS

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Toxcure, LLC, an emerging specialty biopharmaceutical company, today announced the grant of U.S. Patent No. 7,709,440, which provides Toxcure with intellectual property protection for a method of treating various tumors with neurotoxins.

21 May 2010

Caregivers can give complete clinical picture of brain cancer patients' condition

Despite grim prognoses and aggressive treatments, cancer patients suffering from malignant gliomas -- primary brain tumors -- often rate their quality of life more optimistically than their caregivers do, according to a new Northwestern University Feinberg School of Medicine study.

21 May 2010

SLU Hospital announces increase in number of minimally-invasive spinal procedures performed

With the recent launch of the Neurosurgical Spine Program at Saint Louis University Hospital's Center for Cerebrovascular and Skull Base Surgery, the hospital has seen a dramatic increase in the number of minimally-invasive spinal procedures, including lumbar spinal fusion surgery. Designed to stop the motion at a painful vertebral segment, this procedure is traditionally performed via a large incision on the back, stripping vital muscles away from the spine. However, the emergence of minimally-invasive neurosurgical techniques is revolutionizing spinal surgery.

21 May 2010

Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010

Boehringer Ingelheim will announce preliminary data in the areas of head and neck cancer and non-small cell lung cancer for one of the company's investigational compounds, BIBW 2992. These data will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology annual meeting in Chicago.

21 May 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Exelixis, Inc. today reported long-term results in a cohort of 37 medullary thyroid cancer (MTC) patients who participated in the phase 1 study of XL184. Dr. Razelle Kurzrock from the MD Anderson Cancer Center in Houston, TX will present the data in a Clinical Science Symposium (Abstract #5502) on Monday, June 7 at 10:15 AM at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

Biocept granted US patent for cell separation technology using microfluidic device

Biocept, Inc., an emerging leader in rare cell capture, announced today that the U.S. Patent and Trademark Office has issued a patent for Biocept's cell separation technology using a microfluidic device. U.S. patent #7,695,956 entitled "Device for Cell Separation and Analysis and Method of Using" protects Biocept's microflow device to isolate cells from a bodily fluid using a flow path where straight-line flow is interrupted by transverse posts arranged in a random pattern.

21 May 2010

Narrow-band imaging could be novel tool for in vivo assessment of mucosal angiogenesis

Angiogenesis plays a crucial role in neoplastic and non-neoplastic chronic inflammatory disorders, including inflammatory bowel diseases (IBD). Several reports have shown that blockade of angiogenesis in preclinical models of IBD is a promising new therapeutic approach. Visualize angiogenesis in vivo may represent the first step for such a therapeutic approach. Narrow-band imaging (NBI) is a new endoscopic technology that highlights mucosal surface structures and microcapillaries.

21 May 2010

New study reveals PTPN2 gene loss causes bone cancer

In patients with leukemia, the formation of white blood cells in the bone marrow is disrupted. This makes leukemia patients particularly susceptible to infections, because properly functioning white blood cells ensure protection against intruders such as viruses and bacteria.

21 May 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the online-first publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

20 May 2010

Nine facilities in northern California region named Centers of Excellence in accelerated partial breast irradiation

Nine facilities in the northern California region have been named Centers of Excellence in accelerated partial breast irradiation (APBI) for their use of the SAVI® applicator, an advanced therapy for breast cancer as part of breast conservation therapy. The SAVI applicator can provide important advantages for women with early-stage breast cancer.

20 May 2010

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Antigenics today announced that data from a multi-center Phase 1/2 clinical trial of Oncophage (vitespen) for recurrent high-grade glioma (brain cancer) was presented at the International Conference on Brain Tumor Research and Therapy. The study was conducted by the Brain Tumor Research Center at the University of California, San Francisco.

20 May 2010

Mutation in BRCA1 tumor suppressor gene helps develop breast, ovarian cancer: Study

Studies have well established that women who harbor a mutation in the BRCA1 tumor suppressor gene are at greater risk for developing breast and ovarian cancers. Less known is information on other molecular events that may impact cancer formation in cells having a BRCA1 mutation. Investigators from The Cancer Institute of New Jersey and a number of major cancer centers in Europe have identified the role a key protein plays in helping cells with mutant BRCA1 genes to survive.

20 May 2010

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced financial and operational results for the fiscal year ended January 31, 2010.

20 May 2010

Over-expression of Stat5 protein leads to deadly spread of prostate cancer: Study

Researchers from the Kimmel Cancer Center at Jefferson have found that Stat5, a signaling protein previously found to be key to survival of prostate cancer, is also involved in metastasis.

20 May 2010

Study confirms inverse association of increase in BMI with lower brain volumes

Researchers from Boston University School of Medicine determined that excess abdominal fat places otherwise healthy, middle-aged people at risk for dementia later in life. Preliminary findings suggest a relationship between obesity and dementia that could lead to promising prevention strategies in the future. Results of this study are published early online in Annals of Neurology, a journal of the American Neurological Association.

20 May 2010

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.

20 May 2010

Essen BioScience launches CellPlayer Cell Migration 96-well assay kit

Essen BioScience Inc., a global provider of life science research tools and discovery services, today announced the launch of its CellPlayer™ Cell Migration 96-well assay kit for the IncuCyte™ Live-Cell Imaging System. The expanding line of kinetic CellPlayer assays for the IncuCyte also includes a co-culture assay for Angiogenesis.

From Sartorius 19 May 2010

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 will be presented at the annual meeting of the American Society of Clinical Oncology on June 5-7, 2010 in Chicago, IL.

19 May 2010

Parents ignore emotional suffering overweight kids experience as teens

Millions of kids who are obese will likely suffer from verbal abuse, societal ostracization, stigmas, health problems and eventually die at a young age. The double calamity will occur if parents continue to avoid the problem and ignore the cries for help from our children, declares Dr. Sasson Moulavi, M.D., founder of the Smart for Life(R) Cookie Diet and its children's lifestyle program THIN ADVENTURE(TM).

19 May 2010

Researchers discover biological pathway signature of ccRCC

By examining expression of every human gene in clear cell renal cell carcinoma compared to normal kidney cells, researchers at Mayo Clinic's campus in Florida have discovered gene signatures they say explain much of the biology of this common and difficult-to-treat kidney cancer.

19 May 2010

Tumor News and Research

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Caregivers can give complete clinical picture of brain cancer patients' condition

SLU Hospital announces increase in number of minimally-invasive spinal procedures performed

Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Biocept granted US patent for cell separation technology using microfluidic device

Narrow-band imaging could be novel tool for in vivo assessment of mucosal angiogenesis

New study reveals PTPN2 gene loss causes bone cancer

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Nine facilities in northern California region named Centers of Excellence in accelerated partial breast irradiation

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Mutation in BRCA1 tumor suppressor gene helps develop breast, ovarian cancer: Study

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Over-expression of Stat5 protein leads to deadly spread of prostate cancer: Study

Study confirms inverse association of increase in BMI with lower brain volumes

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

Essen BioScience launches CellPlayer Cell Migration 96-well assay kit

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

Parents ignore emotional suffering overweight kids experience as teens

Researchers discover biological pathway signature of ccRCC

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News